Clinical Trials for Testing Of Combination of Oxford and Sputnik Vaccine
Both Adenovirus-Based Vaccines Are Mixed Together To Gain A Better Immune Response
The team of scientists in Russia and the United Kingdom are teaming together for a clinical trial to test the combination dose made from the pre-developed Oxford and Sputnik vaccine to check if the protection and immunity to the individual could be improved from the coronavirus infection. Mixing of two vaccines with similar chemical composition could provide a better immunization response in humans.
Collaboration of Russia and UK’s Oxford University
The clinical trial is scheduled to undergo in Russia and will be involving individuals above the age of 18, although the sample size of the research study is yet to be confirmed for the Oxford and Sputnik vaccine assessment.
According to a recent study published by Oxford, the results suggest that the combined coronavirus vaccine is safe to be injected into people and has shown effective positive results in some experimental cases.
The team of researchers is still continuously collecting new data on the positive reaction and effectiveness of the COVID-19 vaccine in older aged people while awaiting approval from the United Kingdom regulators.
The pharmaceutical firm AstraZeneca stated that they are currently exploring multiple combinations of several developed coronavirus vaccines that are based on adenovirus to check whether the mixing of vaccines could possibly increase the immune response of the body, resulting in greater immunization for the deadly viral pathogen.
The aim of the combination of the Oxford and Sputnik vaccine is to provide better protection and longer duration immunity from the viral infection, which would help save millions of active cases being diagnosed across the world. It is possible that the combined Oxford and Sputnik vaccine would be beneficial for people and could help in increase of effectiveness of the antidote.
Both the vaccines utilize the harmless part of the viral pathogen strain to deliver the required part of the vaccine into the living body.
Mixing adenovirus-based vaccines
The potential risk of the combined Oxford and Sputnik vaccine is it could possibly make the boy immune to the viral postman, which could reduce the effectiveness of the follow-up booster injections of the vaccine.
This is also an explanation for the better conclusive results of the vaccine developed by Oxford University that provided only half the quantity of the dose, which was followed by a complete full dose, rather than injecting two doses with normal quantity.
Other than the developed Oxford and Sputnik vaccine combination, other potential mixtures are also planned with the hope that approaching the problem from different angles could ultimately lead towards a potentially working result.
The British Oxford University vaccine, which was developed with collaboration with pharmaceutical firm AstraZeneca, and the Russian Sputnik V vaccine that was developed by the Gamaleya Research Institute located in Moscow are molecularly similar in structure as they both contain the genetic material from the spike protein inside Sars-CoV-2 virus strain.
The Oxford and Sputnik vaccine is different from the Pfizer-BioNTech coronavirus vaccine, which has gained approval to be used for mass consumption in the United Kingdom, Saudi Arabia, Bahrain, and Canada. The approval is yet to be finalized for the vaccine to be distributed in the United States. The initial results from the last stage trial for the Sputnik V vaccine have provided potential working results to treat coronavirus.
Russia became the first nation across the world to have registered a viable coronavirus vaccine to be used for emergency cases in the month of August, despite being tested on only a small number of people. The vaccine is currently being offered to the general population of Russia as a part of their mass vaccination campaign.
After the announcement for the Oxford and Sputnik vaccine combination, the pharmaceutical company AstraZeneca said that they are working with several industries, government, and research teams across the world and will soon initiate the clinical testing in collaboration with the Russian Gamaleya Research Institute to further understand regarding both vaccines based on adenovirus.